Soligenix Inc (NASDAQ:SNGX) shares surged over 52% in New York as it posted positive data on its ricin toxin vaccine called RiVax.
Ricin is an extremely dangerous poison, which has been used as a weapon and by terrorists.
It can be inhaled, injected, ingested, or absorbed through eyes or damaged skin.
A vaccine against it is hoped to deter its use as a biological weapon.
The firm has shown RiVax has enhanced thermostability and 100% protection in pre-clinical ricin aerosol challenge models and will be showcasing results from the candidate's development program at a conference in Bethesda, Maryland from April 24 to 26.
It is hoped the findings will aid approval of RiVax by the US Food and Drug Administration (FDA).
Shares added 52.87% to $3.93.